Health Care & Life Sciences » Pharmaceuticals | ASKA Pharmaceutical Co. Ltd.

ASKA Pharmaceutical Co. Ltd. | Income Statement

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
2019
Sales/Revenue
39,501
42,907
43,215
48,527
48,944
46,705
Cost of Goods Sold (COGS) incl. D&A
22,446
25,732
26,072
29,614
30,059
27,814
Gross Income
17,055
17,175
17,143
18,913
18,885
18,891
SG&A Expense
16,354
15,768
15,978
17,119
16,060
17,107
EBIT
701
1,410
1,166
1,794
2,825
1,784
Unusual Expense
83
155
287
1,298
10
203
Non Operating Income/Expense
333
441
588
228
264
345
Interest Expense
10
13
20
19
14
41
Pretax Income
947
1,688
1,448
3,300
3,063
1,883
Income Tax
422
530
747
356
674
138
Consolidated Net Income
525
1,158
701
2,944
2,388
1,744
Net Income
495
1,193
701
2,944
2,388
1,744
Net Income After Extraordinaries
495
1,193
701
2,944
2,388
1,744
Net Income Available to Common
495
1,193
701
2,944
2,388
1,744
EPS (Basic)
17.85
42.86
25.14
105.37
84.77
61.80
Basic Shares Outstanding
28
28
28
28
28
28
EPS (Diluted)
17.82
42.86
25.14
105.37
84.77
61.80
Diluted Shares Outstanding
28
28
28
28
28
28
EBITDA
3,175
3,240
3,223
4,295
5,219
4,402
Other Operating Expense
-
3
1
-
-
-
Non-Operating Interest Income
6
5
1
-
-
-
Minority Interest Expense
30
35
-
-
-
-

About ASKA Pharmaceutical Co.

View Profile
Address
2-5-1 Shibaura
Tokyo Tokyo 108
Japan
Employees -
Website http://www.aska-pharma.co.jp
Updated 07/08/2019
ASKA Pharmaceutical Co., Ltd. engages in the manufacture, sale, import and export of pharmaceuticals,veterinary medicines,quasi-drugs,foods,and medical devices. It operates through the following business division: Research and Development. The Research and Development division provides new medicine in R&D system with a balanced combination of cutting-edge pharmaceutical technology and a long experience, to grow and expand persistently as a medium R&D company focusing on a specialized field.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.